» Articles » PMID: 28450344

Chronic Obstructive Pulmonary Disease and Comorbidities: a Large Cross-sectional Study in Primary Care

Overview
Journal Br J Gen Pract
Specialty Public Health
Date 2017 Apr 29
PMID 28450344
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic obstructive pulmonary disease (COPD) is common, and a major cause of morbidity and mortality worldwide. Recent studies suggest that comorbidities of COPD increase the risk of hospitalisation, polypharmacy, and mortality, but their estimated prevalence varies widely in the literature.

Aim: To evaluate the prevalence of 38 physical and mental health comorbidities in people with COPD, and compare findings with those for people without COPD in a large nationally representative dataset.

Design And Setting: A cross-sectional data analysis on 1 272 685 adults in Scotland from 314 primary care practices.

Method: Data on COPD, along with 31 physical and seven mental health comorbidities, were extracted. The prevalence of comorbidities was compared between people who did, and did not, have COPD, standardised by age, sex, and socioeconomic deprivation.

Results: From the total sample, 51 928 patients had COPD (4.1%). Of these, 86.0% had at least one comorbidity, compared with 48.9% of people without COPD. Of those with COPD, 22.3% had ≥5 comorbid conditions compared with 4.9% of those who did not have COPD (adjusted odds ratio 2.63, 95% confidence interval = 2.56 to 2.70). In total, 29 of the 31 physical conditions and six of the seven mental health conditions were statistically significantly more prevalent in people who had COPD than those who did not.

Conclusion: Patients with COPD have extensive associated comorbidities. There is a real need for guidelines and health care to reflect this complexity, including how to detect those common comorbidities that relate to both physical and mental health, and how best to manage them. Primary care, which is unique in terms of offering expert generalist care, is best placed to provide this integrated approach.

Citing Articles

Depression and anxiety disorders in chronic obstructive pulmonary disease patients: Prevalence, disease impact, treatment.

Qiu C, Wu S World J Psychiatry. 2024; 14(12):1797-1803.

PMID: 39704377 PMC: 11622031. DOI: 10.5498/wjp.v14.i12.1797.


Psychiatric Disorders in Patients with Chronic Obstructive Pulmonary Disease: Clinical Significance and Treatment Strategies.

Moretta P, Cavallo N, Candia C, Lanzillo A, Marcuccio G, Santangelo G J Clin Med. 2024; 13(21).

PMID: 39518558 PMC: 11546101. DOI: 10.3390/jcm13216418.


Prevalence and predictors of polypharmacy and comorbidities among patients with chronic obstructive pulmonary disease: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia.

Alwafi H, Naser A, Ashoor D, Alsharif A, Aldhahir A, Alghamdi S BMC Pulm Med. 2024; 24(1):453.

PMID: 39272014 PMC: 11401255. DOI: 10.1186/s12890-024-03274-5.


Patient perspectives on the Tailored intervention for Anxiety and Depression Management in COPD (TANDEM): a qualitative evaluation.

Sohanpal R, Mammoliti K, Barradell A, Kelly M, Newton S, Steed L BMC Health Serv Res. 2024; 24(1):960.

PMID: 39169308 PMC: 11337569. DOI: 10.1186/s12913-024-11370-9.


Increased Risk of Severe Cardiovascular Events Following Exacerbations of Chronic Obstructive Pulmonary Disease: Results of the EXACOS-CV Study in Japan.

Matsunaga K, Yoshida Y, Makita N, Nishida K, Rhodes K, Nordon C Adv Ther. 2024; 41(8):3362-3377.

PMID: 38976123 PMC: 11263248. DOI: 10.1007/s12325-024-02920-y.


References
1.
Nacul L, Soljak M, Samarasundera E, Hopkinson N, Lacerda E, Indulkar T . COPD in England: a comparison of expected, model-based prevalence and observed prevalence from general practice data. J Public Health (Oxf). 2010; 33(1):108-16. DOI: 10.1093/pubmed/fdq031. View

2.
Schnell K, Weiss C, Lee T, Krishnan J, Leff B, Wolff J . The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med. 2012; 12:26. PMC: 3461433. DOI: 10.1186/1471-2466-12-26. View

3.
Sin D, Anthonisen N, Soriano J, Agusti A . Mortality in COPD: Role of comorbidities. Eur Respir J. 2006; 28(6):1245-57. DOI: 10.1183/09031936.00133805. View

4.
Kanazawa H, Yoshikawa J . Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis C virus infection: a 6-year follow-up study. Am J Med. 2004; 116(11):749-52. DOI: 10.1016/j.amjmed.2003.12.026. View

5.
Carstairs V, Morris R . Deprivation and health in Scotland. Health Bull (Edinb). 1990; 48(4):162-75. View